The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tigulixostat Appears Promising for the Treatment of Gout

Tigulixostat Appears Promising for the Treatment of Gout

February 2, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—Tigulixostat is an investigational, non-purine, selective xanthine oxidase inhibitor that lowers serum uric acid (sUA) levels in patients with gout and hyperuricemia. Findings from a phase 2 study were presented by Robert Terkeltaub, MD, professor of medicine and section chief of Rheumatology at the Veterans Administration and University of California, San Diego, at ACR Convergence 2021.1

You Might Also Like
  • Phase 3 Studies Evaluate Lesinurad for Gout Treatment
  • Research Roundup: Abstract Data Presented at ACR Convergence 2021
  • Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica
Explore This Issue
March 2022
Also By This Author
  • FDA Issues Boxed Warning for Hydroxyurea & Neutropenia May Occur after Rituximab Treatments

The researchers randomized 156 patients with gout and sUA levels of ≥8.0 mg/dL to ≤12.0 mg/dL to receive 50 mg of tigulixostat (n=34), 100 mg of tigulixostat (n=38), 200 mg of tigulixostat (n=37) or placebo (n=34) once daily for 12 weeks. Prior to treatment, the patients underwent a wash-out period during which they took 0.6 mg of colchicine once daily for gout flare prophylaxis. Colchicine was continued until the end of the study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study goal was to evaluate the efficacy and safety of tigulixostat in gout patients with hyperuricemia, as well as to find appropriate doses for further development. The primary end point was the proportion of patients who achieved an sUA level less than 5 mg/dL at week 12. The secondary end points included the proportion of patients who attained an sUA level less than 6 mg/dL at week 12 and gout flare data collected using an electronic diary. Safety was assessed throughout the study, including during a two-week, post-treatment follow-up visit.

The Results

At week 12, 2.9% of patients who received placebo achieved an sUA level of less than 5.0 mg/dL compared with 47% of patients who received 50 mg of tigulixostat, 45% who received 100 mg of tigulixostat and 62% who received 200 mg of tigulixostat. The findings were statistically significant for all tigulixostat doses compared with placebo (P<0.0001).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Also at week 12, the rates of patients who achieved an sUA level of less than 6 mg/dL were significantly higher for those who received tigilixostat than those who received placebo (P<0.0001, for all doses). The response levels of patients who received tigulixostat were 59% for 50 mg of tigulixostat, 63% for 100 mg of tigulixostat and 78% for 200 mg of tigulixostat compared with 3% for patients who received placebo.

The total percentage of gout flares were: 13% for patients who received both 50 mg and 100 mg of tigulixostat, 11% for patients who received 200 mg of tigulixostat and 9% for patients who received placebo. All patients who experienced a flare required rescue treatment.

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, Crystal Arthritis, Drug Updates, Meeting Reports Tagged With: ACR Convergence – Gout, ACR Convergence 2021, ACR Convergence 2021 – Gout, Gout, serum uric acid, tigulixostatIssue: March 2022

You Might Also Like:
  • Phase 3 Studies Evaluate Lesinurad for Gout Treatment
  • Research Roundup: Abstract Data Presented at ACR Convergence 2021
  • Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica
  • Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)